Australia's most trusted
source of pharma news
Thursday, 10 July 2025
Posted 8 July 2025 AM
Eight drugs that secured a recommendation at the PBAC’s controversial March meeting have since stalled in the PBS listing process with the submissions for reimbursement marked inactive.
Three of the four generalised myasthenia gravis (gMG) treatments recommended at the meeting - are currently considered inactive.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.